POLARIS: Encorafenib Plus Binimetinib for People With BRAF V600-Mutant Melanoma With Brain Metastasis

Authors

Alexander M Menzies
Michael A Davies

Publication Date

7-1-2025

Journal

Future Oncology

DOI

10.1080/14796694.2025.2514426

PMID

40503961

PMCID

PMC12266674

PubMedCentral® Posted Date

7-12-2025

PubMedCentral® Full Text Version

Post-print

Abstract

POLARIS was a study to evaluate different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. The first part, known as the safety lead-in, looked at a high dose of encorafenib (300 mg twice daily) combined with standard binimetinib (45 mg twice daily); in the phase 2 part, patients were given the standard dose of encorafenib (450 mg once daily) plus binimetinib. In the safety lead-in, many patients were unable to tolerate the high dose of encorafenib plus binimetinib. Despite recruitment challenges in POLARIS, in the 13 enrolled patients with unresectable metastatic BRAF V600-mutant melanoma with brain metastases, treatment with encorafenib plus binimetinib demonstrated intracranial activity, with a brain metastasis response rate of over 60%.

Keywords

Humans, Proto-Oncogene Proteins B-raf, Brain Neoplasms, Melanoma, Carbamates, Sulfonamides, Benzimidazoles, Antineoplastic Combined Chemotherapy Protocols, Middle Aged, Female, Male, Mutation, Aged, Adult, Treatment Outcome, Skin Neoplasms

Published Open-Access

yes

Recommended Citation

Alexander M Menzies and Michael A Davies, "POLARIS: Encorafenib Plus Binimetinib for People With BRAF V600-Mutant Melanoma With Brain Metastasis" (2025). Faculty, Staff and Student Publications. 4332.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4332